|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
From 2008 to 2017, all 26 consecutive newborn infants ≥35 weeks of gestation diagnosed with neonatal CSVT, and their mothers, were tested for factor V Leiden (FV) G1691A, FII G20210A, and methylenetetrahydrofolate reductase C677T (MTHFR C677T) mutations.
|
31025572 |
2019 |
|
Thrombophilia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ancillary testing revealed inherited thrombophilia (Prothrombin 20,210 G > A and MTHFR 677 C > T mutation).
|
29299826 |
2018 |
|
Hyperhomocysteinemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Risk factors reviewed include myeloproliferative neoplasms (MPNs) and their related gene mutations, anti-phospholipid syndrome, paroxysmal nocturnal haemoglobinuria (PNH), hyperhomocysteinaemia and 5,10-methylenetetrahydrofolate reductase (MTHFR) C677T mutation, factor V Leiden (FVL) and prothrombin G20210A mutations, inherited anti-thrombin, protein C and protein S deficiencies, pregnancy and puerperium, poverty, and family history.
|
27734511 |
2016 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
IVF outcomes are not associated with FVL, PGM, MTHFR (C677T), MTHFR (A1298C), and APCR mutation in inherited thrombophilias.
|
27216921 |
2016 |
|
Thrombophilia
|
|
0.100 |
GeneticVariation
|
BEFREE |
The important polymorphisms leading to inherited thrombophilia are Factor V Leiden (FVL), Prothrombin G20210A and MTHFR C677T and A1298C.
|
26135458 |
2016 |
|
Thrombophilia
|
|
0.100 |
GeneticVariation
|
BEFREE |
IVF outcomes are not associated with FVL, PGM, MTHFR (C677T), MTHFR (A1298C), and APCR mutation in inherited thrombophilias.
|
27216921 |
2016 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our study revealed mutations in hemophilia patients as follows: prothrombin G20210A (3 %), FVL (14 %), MTHFR C677T (42 %), and A1298C (59 %).
|
26891731 |
2016 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
The -675 4G/5G PAI-1 allele distribution differed significantly between patients and controls (P = 0.020), but no difference was found regarding the distribution of -844 G/A PAI-1 (P = 0.493), FVL (P = 0.199), FIIG20210A (P = 0.410), FXIII-AVal34leu (P = 0.160) and C677T MTHFR (P = 0.788).
|
25699610 |
2015 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
We aimed to determine the prevalence of factor V Leiden (FVL), prothrombin (PTH) G20210A and methylene tetrahydrofolate reductase (MTHFR) C677T gene polymorphisms in Egyptian nonmetastatic cancer patients and their influence on thrombosis risk in those patients.
|
25565385 |
2015 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Factor V Leiden, PTH G20210A and MTHFR C677T polymorphisms were detected in 40 cancer patients with VTE (group 1) and 40 cancer patients with no evidence of VTE (group 2) by PCR-based DNA analysis.
|
25565385 |
2015 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
MTHFR C677T had no association with VTE risk in pregnancy (ORG 1.24; 95% CI 0.88-1.73).
|
26115054 |
2015 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
Three common polymorphic variants, namely Factor V Leiden (FVL), Prothrombin G20210A (PT G20210A) and Methylenetetrahydrofolate Reductase (MTHFR) C677T are candidate genes for venous thromboembolism (VTE) in pregnancy.
|
26115054 |
2015 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
Factor V Leiden (FVL) G1691A, Prothrombin (PT) G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T and A128C mutations were evaluated in children with moderate-severe hemophilia A (n = 51) and controls (n = 25).
|
22411997 |
2014 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
No significant association with VTE was found for homozygous C677T MTHFR (OR: 1.38; 95 % confidence intervals [CI]: 0.98-1.93), whereas the risk was increased in carriers of either heterozygous FVL or PT20210 (OR = 4.22; 95 % CI: 3.35-5.32; and OR = 2.79;95 % CI: 2.25-3.46, respectively), in double heterozygotes (OR = 3.42; 95 %CI 1.64-7.13), and in homozygous FVL or PT20210A (OR = 11.45; 95 %CI: 6.79-19.29; and OR: 6.74 (CI 95 % 2.19-20.72), respectively).
|
23900608 |
2013 |
|
Hyperhomocysteinemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
All participants had a thrombotic workup that included the following: genetic markers: factor V Leiden G1691A and G20210A prothrombin mutations, methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms; protein assays: protein C, protein S and antithrombin; other tests: blood typing and screening for hyperhomocysteinemia.
|
23337711 |
2013 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
We analysed the prevalence of the most common hereditary thrombophilia (hTP) - factor V Leiden (FVL) mutation, prothrombin 20210 G>A substitution (PT) - and the 677 C>T replacement in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene in Caucasian patients with a history of two and more consecutive recurrent miscarriages (RMs) as compared to healthy controls with an identical ethnic background and at least one live birth.
|
23795816 |
2013 |
|
Hyperhomocysteinemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Out of three homozygous cases for C677T MTHFR polymorphism, two of these patients had hy</span>perhomocysteinemia.
|
23337710 |
2013 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
We determined whether the presence of the factor prothrombin gene G20210A variant, factor V gene G1691A mutation (factor V Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T polymorphisms may be risk factors for vascular complications in individuals with SCD.
|
23992124 |
2013 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
The three genes were involved in thrombophilia: factor V Leiden (G1691A), prothrombin (G20210A), Methylenetetrahydrofolate Reductase (MTHFR C677T) and one in hypofibrinolysis: Tissue Plasminogen Activator (PLAT TPA25 I/D).
|
24025446 |
2013 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
The genetic polymorphisms C677T and A1298C relating to the enzyme methylenetetrahydrofolate reductase (MTHFR), a clotting Factor V Leiden mutation (1691G→A substitution of Factor V Leiden), and the mutant prothrombin 20210A allele were analyzed in this study.
|
22924497 |
2012 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
In infants with atypical PVHI mutation analysis of the factor V Leiden (G1691A), prothrombin (G20210A) gene, and C677T and A1298C polymorphisms in the MTHFR gene was performed, and plasma lipoprotein(a) and homocysteine levels were measured.
|
22098125 |
2012 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Factor V leiden G1691A/R506Q (FVL), prothrombin G20210A (FII) and methylenetetrahydrofolate reductase (MTHFR) C677T are related genetic risk factors for venous thromboembolism.
|
22528331 |
2012 |
|
Venous Thromboembolism
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, frequencies of FV G1691A, PT G20210A, and MTHFR C677T mutations are higher in patients with VTE.
|
21078611 |
2012 |
|
Thrombophilia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Factor V Leiden G1691A, prothrombin G20210A, MTHFR C677T, and Factor XII C46T mutations are associated with the risk of developing thrombophilia.
|
22521752 |
2012 |
|
Factor V Leiden mutation
|
|
0.100 |
GeneticVariation
|
BEFREE |
The homozygosity of 4G in PAI-1 and MTHFR C677T genes in women with RPL, and heterozygosity of FVL, FVR2, ACE, and ApoE2 genes in both parents play crucial role in RPL and should be considered as a risk factor in RPL.
|
22047507 |
2012 |